Validation of fluorouracil metabolite analysis in excised tumor: Lability of anabolites

Biochemical Pharmacology

Volumn 60, Issue 7, 2000, Pages 963-967

  Bading, James R ^a   Shahinian, Antranik H ^a   Paff, Melanie T ^b   Yoo, Paul B ^a   Hsia, David W ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Adenocarcinoma; Antimetabolites; Biological assay; Fluorouracil; Metabolism; Pyrimidines

Indexed keywords

5 ETHYNYLURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLITE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; NUCLEOSIDE TRIPHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TRANSPLANTATION; COLON TUMOR; DRUG DETERMINATION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; FLUOROURACIL; RADIOPHARMACEUTICALS; RATS; RATS, INBRED F344; TRITIUM;

EID: 0034308181     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00421-4     Document Type: Article

References (14)

1. Bading J.R., Alauddin M.M., Fissekis J.H., Kirkman E., Raman R.K., Conti P.S. Blocking catabolism enhances PET studies of 5-[F-18]fluorouracil pharmacokinetics. J Nucl Med. 38:1997;176P.
2. Rustum Y.M. Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin. Cancer. 63:1989;1013-1017.
3. Cao S., Rustum Y.M., Spector T. 5-Ethynyluracil (776C85), Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res. 54:1994;1507-1510.
4. Cao S., Frank C., Shirasaka T., Rustum Y.M. 5-Fluorouracil prodrug Role of anabolic and catabolic pathway modulation in therapy of colorectal cancer . Clin Cancer Res. 1:1995;839-845.
5. Cao S., Frank C., Rustum Y.M. Role of fluoropyrimidine schedule and (6R,S) leucovorin dose in a preclinical animal model of colorectal carcinoma. J Natl Cancer Inst. 88:1996;430-436.
6. Spector T., Porter D.J.T., Nelson D.J., Baccanari D.P., Davis S.T., Almond M.R., Khor S.P., Amyx H., Cao S., Rustum Y.M. 5-Ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracil. Drugs Future. 19:1994;565-571.
7. Fischel J.L., Etienne M.C., Spector T., Formento P., Renee N., Milano G. Dihydropyrimidine dehydrogenase A tumoral target for fluorouracil modulation . Clin Cancer Res. 1:1995;991-996.
8. Houghton J.A., Houghton P.J. On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon xenografts maintained in immune-depressed mice. Cancer. 45:1980;1159-1167.
9. Wolberg W.H., Morin J. Thymidylate synthetase activity and fluorouracil sensitivity of human colonic cancer and normal mucosal tissue preparations. Cancer. 47:1981;1313-1317.
10. 3H-deoxythymidine in tumor-bearing rats and mice . Eur J Nucl Med. 10:1985;39-44.
11. Berne M.H.O., Gustavsson B.G., Almersjo O., Spears P.C., Frosing R. Sequential methotrexate/5-FU:FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma. Cancer Chemother Pharmacol. 16:1986;237-242.
12. Spears C.P., Gustavsson B.G., Berne M., Frosing R., Bernstein L., Hayes A.A. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res. 48:1988;5894-5900.
13. 19F nuclear magnetic resonance spectroscopy. Cancer Res. 51:1991;5806-5812.
14. 19F nuclear magnetic resonance spectroscopy. Cancer Res. 59:1999;122-127.